

9. Literaturverzeichnis

1. Armstrong, B. 2004. *Epidemiology of cutaneous melanoma and current trends*. Martin Dunitz, London.
2. Meyskens, F. L., Jr., P. J. Farmer, and H. Anton-Culver. 2004. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. *Clin Cancer Res* 10:2581.
3. Bliss, J. M., D. Ford, A. J. Swerdlow, B. K. Armstrong, M. Cristofolini, J. M. Elwood, A. Green, E. A. Holly, T. Mack, R. M. MacKie, and et al. 1995. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). *Int J Cancer* 62:367.
4. Ford, D., J. M. Bliss, A. J. Swerdlow, B. K. Armstrong, S. Franceschi, A. Green, E. A. Holly, T. Mack, R. M. MacKie, A. Osterlind, and et al. 1995. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). *Int J Cancer* 62:377.
5. Lens, M. B., and M. Dawes. 2004. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. *Br J Dermatol* 150:179.
6. Beddingfield, F. C., 3rd. 2003. The melanoma epidemic: res ipsa loquitur. *Oncologist* 8:459.
7. Giles, G. G., B. K. Armstrong, R. C. Burton, M. P. Staples, and V. J. Thursfield. 1996. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. *Bmj* 312:1121.
8. Heinzerling, L. M., R. Dummer, R. G. Panizzon, P. H. Bloch, R. Barbezat, and G. Burg. 2002. Prevention campaign against skin cancer. *Dermatology* 205:229.
9. Heinzerling, L. 2004. Melanomprävention in Australien. *Hautnah*.
10. Kleeberg, U. R., S. Suci, E. B. Brocker, D. J. Ruiter, C. Chartier, D. Lienard, J. Marsden, D. Schadendorf, and A. M. Eggermont. 2004. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. *Eur J Cancer* 40:390.
11. Wheatley, K., N. Ives, B. Hancock, and M. Gore. 2002. Interferon as adjuvant treatment for melanoma. *Lancet* 360:878.
12. Balch, C. M., S. J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, K. M. McMasters, M. I. Ross, J. M. Kirkwood, M. B. Atkins, J. A. Thompson, D. G. Coit, D. Byrd, R. Desmond, Y. Zhang, P. Y. Liu, G. H. Lyman, and A. Morabito. 2001. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 19:3622.
13. Balch, C. M., A. C. Buzaid, S. J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton, Jr., J. M. Kirkwood, K. M. McMasters, M. F. Mihm, D. L. Morton, D. S. Reintgen, M. I. Ross, A. Sober, J. A. Thompson, and J. F. Thompson. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol* 19:3635.

14. Manola, J., M. Atkins, J. Ibrahim, and J. Kirkwood. 2000. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. *J Clin Oncol* 18:3782.
15. Schaffer, J. V., D. S. Rigel, A. W. Kopf, and J. L. Bolognia. 2004. Cutaneous melanoma--past, present, and future. *J Am Acad Dermatol* 51:S65.
16. Cameron, D. A., M. C. Cornbleet, R. M. Mackie, J. A. Hunter, M. Gore, B. Hancock, and J. F. Smyth. 2001. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. *Br J Cancer* 84:1146.
17. Grob, J. J., B. Dreno, P. de la Salmoniere, M. Delaunay, D. Cupissol, B. Guillot, P. Souteyrand, B. Sassolas, J. P. Cesarini, S. Lionnet, C. Lok, C. Chastang, and J. J. Bonerandi. 1998. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. *Lancet* 351:1905.
18. Garbe, C. 2005. *Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren*. Georg Thieme Verlag, Stuttgart.
19. Essner, R., A. Conforti, M. C. Kelley, L. Wanek, S. Stern, E. Glass, and D. L. Morton. 1999. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. *Ann Surg Oncol* 6:442.
20. White, R. R., W. E. Stanley, J. L. Johnson, D. S. Tyler, and H. F. Seigler. 2002. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. *Ann Surg* 235:879.
21. Tsao, H., M. B. Atkins, and A. J. Sober. 2004. Management of cutaneous melanoma. *N Engl J Med* 351:998.
22. Leo, F., L. Cagini, P. Rocmans, M. Cappello, A. N. Geel, G. Maggi, P. Goldstraw, and U. Pastorino. 2000. Lung metastases from melanoma: when is surgical treatment warranted? *Br J Cancer* 83:569.
23. Thompson, J., S. Menzies, H. Shaw, R. Scolyer, and R. Kefford. 2005. Cutaneous melanoma. *Lancet* 365:2004.
24. Fowler, B. Z., I. R. Crocker, and P. A. Johnstone. 2005. Perineural spread of cutaneous malignancy to the brain: a review of the literature and five patients treated with stereotactic radiotherapy. *Cancer* 103:2143.
25. Buchsbaum, J. C., J. H. Suh, S. Y. Lee, M. A. Chidel, J. F. Greskovich, and G. H. Barnett. 2002. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. *Cancer* 94:2265.
26. Kirova, Y. M., J. Chen, L. I. Rabarijaona, Y. Piedbois, and J. P. Le Bourgeois. 1999. Radiotherapy as palliative treatment for metastatic melanoma. *Melanoma Res* 9:611.
27. Chiarion Sileni, V., R. Nortilli, S. M. Aversa, A. Paccagnella, M. Medici, L. Corti, A. G. Favaretto, G. L. Cetto, and S. Monfardini. 2001. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. *Melanoma Res* 11:189.
28. Moon, J. H., S. Gailani, M. R. Cooper, D. M. Hayes, V. B. Rege, J. Blom, G. Falkson, P. Maurice, K. Brunner, O. Glidewell, and J. F. Holland. 1975. Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino)imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. *Cancer* 35:368.

29. Retsas, S., K. A. Newton, and G. Westbury. 1979. Vindesine as a single agent in the treatment of advanced malignant melanoma. *Cancer Chemother Pharmacol* 2:257.
30. Bleehen, N. M., E. S. Newlands, S. M. Lee, N. Thatcher, P. Selby, A. H. Calvert, G. J. Rustin, M. Brampton, and M. F. Stevens. 1995. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. *J Clin Oncol* 13:910.
31. Keilholz, U., S. H. Goey, C. J. Punt, T. M. Proebstle, R. Salzmann, C. Scheibenbogen, D. Schadendorf, D. Lienard, A. Enk, R. Dummer, B. Hantich, A. M. Geueke, and A. M. Eggermont. 1997. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. *J Clin Oncol* 15:2579.
32. McDermott, D. F., J. W. Mier, D. P. Lawrence, M. R. van den Brink, M. A. Clancy, K. M. Rubin, and M. B. Atkins. 2000. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. *Clin Cancer Res* 6:2201.
33. Chapman, P. B., L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, A. N. Houghton, and J. M. Kirkwood. 1999. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol* 17:2745.
34. Middleton, M. R., J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher. 2000. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 18:158.
35. Mornex, F., L. Thomas, P. Mohr, A. Hauschild, M. M. Delaunay, T. Lesimple, W. Tilgen, B. N. Bui, B. Guillot, J. Ulrich, S. Bourdin, M. Mousseau, D. Cupissol, M. E. Bonnetterre, C. De Gislain, R. J. Bensadoun, and M. Clavel. 2003. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. *Melanoma Res* 13:97.
36. Rosenberg, S. A., J. C. Yang, D. E. White, and S. M. Steinberg. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. *Ann Surg* 228:307.
37. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 17:2105.
38. Dummer, R., A. Hauschild, T. Henseler, and G. Burg. 1998. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma. *Lancet* 352:908.
39. Haffner, A. C., C. Garbe, G. Burg, P. Buttner, C. E. Orfanos, and G. Rassner. 1992. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. *Br J Cancer* 66:856.

40. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, A. Bourlond, R. Vanwijck, D. Lienard, M. Beauduin, P. Y. Dietrich, V. Russo, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P. G. Coulie, P. van der Bruggen, and T. Boon. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80:219.
41. Duran Garcia, E., R. Santolaya, and T. Requena. 1999. Treatment of malignant melanoma. *Ann Pharmacother* 33:730.
42. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 4:328.
43. Stopeck, A. T., A. Jones, E. M. Hersh, J. A. Thompson, D. M. Finucane, J. C. Gutheil, and R. Gonzalez. 2001. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. *Clin Cancer Res* 7:2285.
44. Parmiani, G., C. Castelli, L. Rivoltini, C. Casati, G. A. Tully, L. Novellino, A. Patuzzo, D. Tosi, A. Anichini, and M. Santinami. 2003. Immunotherapy of melanoma. *Semin Cancer Biol* 13:391.
45. Schadendorf, D., A. Paschen, and Y. Sun. 2000. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. *Immunol Lett* 74:67.
46. Lawson, D. H. 2004. Update on the systemic treatment of malignant melanoma. *Semin Oncol* 31:33.
47. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. *Blood* 84:4008.
48. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. *Adv Immunol* 70:83.
49. Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. *J Exp Med* 173:869.
50. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. *J Exp Med* 170:827.
51. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, F. Liao, J. M. Farber, S. Pestka, G. Trinchieri, and W. M. Lee. 1998. Tumor cell responses to IFN γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. *Immunity* 9:25.
52. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1:27.
53. Morini, M., A. Albini, G. Lorusso, K. Moelling, B. Lu, M. Cilli, S. Ferrini, and D. M. Noonan. 2003. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immuno-gene therapy. *Gene Ther* 11(3):284-91.
54. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. *J Natl Cancer Inst* 87:581.

55. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. *J Exp Med* 182:155.
56. Motzer, R. J., A. Rakhit, L. H. Schwartz, T. Olencki, T. M. Malone, K. Sandstrom, R. Nadeau, H. Parmar, and R. Bukowski. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. *Clin Cancer Res* 4:1183.
57. Robertson, M. J., C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz. 1999. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. *Clin Cancer Res* 5:9.
58. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, J. W. Mier, C. M. Canning, L. Battiato, H. Tahara, and M. L. Sherman. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. *Clin Cancer Res* 3:409.
59. Bajetta, E., M. Del Vecchio, R. Mortarini, R. Nadeau, A. Rakhit, L. Rimassa, C. Fowst, A. Borri, A. Anichini, and G. Parmiani. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. *Clin Cancer Res* 4:75.
60. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. *Blood* 90:2541.
61. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. *Science* 270:908.
62. Brunda, M. J., L. Luistro, R. R. Warriar, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. *J Exp Med* 178:1223.
63. Coughlin, C. M., M. Wysocka, H. L. Kurzawa, W. M. Lee, G. Trinchieri, and S. L. Eck. 1995. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. *Cancer Res* 55:4980.
64. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M. P. Colombo. 1996. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. *Cancer Res* 56:467.
65. Teicher, B. A., G. Ara, K. Menon, and R. G. Schaub. 1996. In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. *Int J Cancer* 65:80.
66. Golab, J., T. Stoklosa, R. Zagozdzon, A. Kaca, A. Giermasz, Z. Pojda, E. Machaj, A. Dabrowska, W. Feleszko, W. Lasek, A. Iwan-Osiecka, and M. Jakobisiak. 1998. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. *Ann Oncol* 9:63.
67. Kurzawa, H., M. Wysocka, E. Aruga, A. E. Chang, G. Trinchieri, and W. M. Lee. 1998. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. *Cancer Res* 58:491.
68. Kikuchi, T., T. Joki, S. Saitoh, Y. Hata, T. Abe, N. Kato, A. Kobayashi, T. Miyazaki, and T. Ohno. 1999. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. *Int J Cancer* 80:425.

69. Tahara, H., H. J. Zeh, 3rd, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. *Cancer Res* 54:182.
70. Tahara, H., M. T. Lotze, P. D. Robbins, W. J. Storkus, and L. Zitvogel. 1995. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. *Hum Gene Ther* 6:1607.
71. Tahara, H., L. Zitvogel, W. J. Storkus, P. D. Robbins, and M. T. Lotze. 1996. Murine models of cancer cytokine gene therapy using interleukin-12. *Ann N Y Acad Sci* 795:275.
72. Meko, J. B., K. Tsung, and J. A. Norton. 1996. Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12. *Surgery* 120:274.
73. Popovic, D., K. M. El-Shami, E. Vadai, M. Feldman, E. Tzehoval, and L. Eisenbach. 1998. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12. *Clin Exp Metastasis* 16:623.
74. Aruga, A., K. Tanigawa, E. Aruga, H. Yu, and A. E. Chang. 1999. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. *Cancer Gene Ther* 6:89.
75. Matsumoto, G., M. Sunamura, H. Shimamura, T. Kodama, W. Hashimoto, M. Kobari, K. Kato, K. Takeda, H. Yagita, K. Okumura, H. Hamada, and S. Matsuno. 1999. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. *Surgery* 125:257.
76. Rodolfo, M., C. Zilocchi, B. Cappetti, G. Parmiani, C. Melani, and M. P. Colombo. 1999. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. *Gene Ther* 6:865.
77. Lipps, H. J., and J. Bode. 2001. Exploiting chromosomal and viral strategies: the design of safe and efficient non-viral gene transfer systems. *Curr Opin Mol Ther* 3:133.
78. Stoll, S. M., and M. P. Calos. 2002. Extrachromosomal plasmid vectors for gene therapy. *Curr Opin Mol Ther* 4:299.
79. Meko, J. B., J. H. Yim, K. Tsung, and J. A. Norton. 1995. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. *Cancer Res* 55:4765.
80. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. *Hum Gene Ther* 7:1995.
81. Putzer, B. M., M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham. 1997. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. *Proc Natl Acad Sci U S A* 94:10889.
82. Asselin-Paturel, C., N. Lassau, J. M. Guinebretiere, J. Zhang, F. Gay, F. Bex, S. Hallez, J. Leclere, P. Peronneau, F. Mami-Chouaib, and S. Chouaib. 1999. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus

- vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. *Gene Ther* 6:606.
83. Toda, M., R. L. Martuza, H. Kojima, and S. D. Rabkin. 1998. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. *J Immunol* 160:4457.
 84. Siders, W. M., P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltout, and R. G. Fenton. 1998. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. *J Immunol* 160:5465.
 85. Addison, C. L., J. L. Bramson, M. M. Hitt, W. J. Muller, J. Gaudie, and F. L. Graham. 1998. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. *Gene Ther* 5:1400.
 86. Gambotto, A., T. Tuting, D. L. McVey, I. Kovesdi, H. Tahara, M. T. Lotze, and P. D. Robbins. 1999. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. *Cancer Gene Ther* 6:45.
 87. Emtage, P. C., Y. Wan, M. Hitt, F. L. Graham, W. J. Muller, A. Zlotnik, and J. Gaudie. 1999. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. *Hum Gene Ther* 10:697.
 88. Hirschowitz, E. A., and R. G. Crystal. 1999. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases. *Am J Respir Cell Mol Biol* 20:935.
 89. Davidoff, A. M., S. A. Kimbrough, C. Y. Ng, S. J. Shochat, and E. F. Vanin. 1999. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. *J Pediatr Surg* 34:902.
 90. Mazzolini, G., C. Qian, X. Xie, Y. Sun, J. J. Lasarte, M. Drozdik, and J. Prieto. 1999. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. *Cancer Gene Ther* 6:514.
 91. Rakhmievich, A. L., J. G. Timmins, K. Janssen, E. L. Pohlmann, M. J. Sheehy, and N. S. Yang. 1999. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. *J Immunother* 22:135.
 92. Rakhmievich, A. L., K. Janssen, J. Turner, J. Culp, and N. S. Yang. 1997. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. *Hum Gene Ther* 8:1303.
 93. Wang, C., M. E. Quevedo, B. J. Lannutti, K. B. Gordon, D. Guo, W. Sun, and A. S. Paller. 1999. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. *J Invest Dermatol* 112:775.
 94. Tan, J., N. S. Yang, J. G. Turner, G. L. Niu, H. F. Maassab, J. Sun, M. L. Herlocher, A. E. Chang, and H. Yu. 1999. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. *Cancer Gene Ther* 6:331.
 95. Mendiratta, S. K., A. Quezada, M. Matar, J. Wang, H. L. Hebel, S. Long, J. L. Nordstrom, and F. Pericle. 1999. Intratumoral delivery of IL-12 gene by

- polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. *Gene Ther* 6:833.
96. Blezinger, P., B. D. Freimark, M. Matar, E. Wilson, A. Singhal, W. Min, J. L. Nordstrom, and F. Pericle. 1999. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. *Hum Gene Ther* 10:723.
 97. Heinzerling, L., G. Burg, R. Dummer, T. Maier, P. A. Oberholzer, J. Schultz, L. Elzaouk, J. Pavlovic, and K. Moelling. 2005. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. *Hum Gene Ther* 16:35.
 98. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, J. W. Mier, C. M. Canning, L. Battiato, H. Tahara, and M. L. Sherman. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. *Clin Cancer Res* 3:409.
 99. Zeuzem, S., U. Hopf, V. Carreno, M. Diago, M. Shiffman, S. Grune, F. J. Dudley, A. Rakhit, K. Rittweger, S. H. Yap, R. S. Koff, and H. C. Thomas. 1999. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. *Hepatology* 29:1280.
 100. Portielje, J. E., W. H. Kruit, M. Schuler, J. Beck, C. H. Lamers, G. Stoter, C. Huber, M. de Boer-Dennert, A. Rakhit, R. L. Bolhuis, and W. E. Aulitzky. 1999. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. *Clin Cancer Res* 5:3983.
 101. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. *Clin Cancer Res* 6:1678.
 102. Lotze, M. T., L. Zitvogel, R. Campbell, P. D. Robbins, E. Elder, C. Haluszczak, D. Martin, T. L. Whiteside, W. J. Storkus, and H. Tahara. 1996. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. *Ann N Y Acad Sci* 795:440.
 103. Lotze, M. T., B. Hellerstedt, L. Stolinski, T. Tueting, C. Wilson, D. Kinzler, H. Vu, J. T. Rubin, W. Storkus, H. Tahara, E. Elder, and T. Whiteside. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. *Cancer J Sci Am* 3 Suppl 1:S109.
 104. Sun, Y., K. Jurgovsky, P. Moller, S. Alijagic, T. Dorbic, J. Georgieva, B. Wittig, and D. Schadendorf. 1998. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. *Gene Ther* 5:481.
 105. Kang, W. K., C. Park, H. L. Yoon, W. S. Kim, S. S. Yoon, M. H. Lee, K. Park, K. Kim, H. S. Jeong, J. A. Kim, S. J. Nam, J. H. Yang, Y. I. Son, C. H. Baek, J. Han, H. J. Ree, E. S. Lee, S. H. Kim, D. W. Kim, Y. C. Ahn, S. J. Huh, Y. H. Choe, J. H. Lee, M. H. Park, G. S. Kong, E. Y. Park, Y. K. Kang, Y. J. Bang, N. S. Paik, S. N. Lee, S. Kim, P. D. Robbins, H. Tahara, M. T. Lotze, and C. H. Park. 2001. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. *Hum Gene Ther* 12:671.
 106. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller, B. S. McEwen, and C. A. Biron. 1995. Mechanism of interleukin 12-mediated

- toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. *J Exp Med* 181:901.
107. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. *Int Immunol* 6:157.
 108. Bree, A. G., F. J. Schlerman, M. D. Kaviani, R. C. Hastings, S. L. Hitz, and S. J. Goldman. 1994. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. *Biochem Biophys Res Commun* 204:1150.
 109. Rochlitz, C., B. Dreno, P. Jantscheff, F. Cavalli, P. Squiban, B. Acres, M. Baudin, B. Escudier, L. Heinzerling, R. Morant, R. Herrmann, P. Y. Dietrich, and R. Dummer. 2002. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. *Cancer Gene Ther* 9:289.
 110. Ma, H., and S. L. Diamond. 2001. Nonviral gene therapy and its delivery systems. *Current Pharmaceutical Biotechnology* 2:1.
 111. Krieg, A. M., A. K. Yi, and G. Hartmann. 1999. Mechanisms and therapeutic applications of immune stimulatory cpG DNA. *Pharmacol Ther* 84:113.
 112. Krieg, A. M., and H. L. Davis. 2001. Enhancing vaccines with immune stimulatory CpG DNA. *Curr Opin Mol Ther* 3:15.
 113. Yanez, R. J., and A. C. Porter. 1998. Therapeutic gene targeting. *Gene Ther* 5:149.
 114. Prud'homme, G. J. 2005. DNA vaccination against tumors. *J Gene Med* 7:3.
 115. Heinzerling, L. M., K. Feige, S. Rieder, M. K. Akens, R. Dummer, G. Stranzinger, and K. Moelling. 2001. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. *J Mol Med* 78:692.
 116. Alatrash, G., T. E. Hutson, L. Molto, A. Richmond, C. Nemecek, T. Mekhail, P. Elson, C. Tannenbaum, T. Olencki, J. Finke, and R. M. Bukowski. 2004. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. *J Clin Oncol* 22:2891.
 117. Triozzi, P. L., K. O. Allen, R. R. Carlisle, M. Craig, A. F. LoBuglio, and R. M. Conry. 2005. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. *Clin Cancer Res* 11:4168.
 118. van Herpen, C. M., J. A. van der Laak, I. J. de Vries, J. H. van Krieken, P. C. de Wilde, M. G. Balvers, G. J. Adema, and P. H. De Mulder. 2005. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. *Clin Cancer Res* 11:1899.
 119. Schultz, J., L. Heinzerling, J. Pavlovic, and K. Moelling. 2000. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. *Cancer Gene Ther* 7:1557.
 120. Segal, J. G., N. C. Lee, Y. L. Tsung, J. A. Norton, and K. Tsung. 2002. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target. *Cancer Res* 62:4696.

121. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. *Cytokine Growth Factor Rev* 13:95.
122. Morini, M., A. Albin, G. Lorusso, K. Moelling, B. Lu, M. Cilli, S. Ferrini, and D. M. Noonan. 2004. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. *Gene Ther* 11:284.
123. Heinzerling, L., R. Dummer, J. Pavlovic, J. Schultz, G. Burg, and K. Moelling. 2002. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. *Exp Dermatol* 11:232.
124. Schultz, J., J. Pavlovic, B. Strack, M. Nawrath, and K. Moelling. 1999. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. *Hum Gene Ther* 10:407.
125. Keyser, J., J. Schultz, K. Ladell, L. Elzaouk, L. Heinzerling, J. Pavlovic, and K. Moelling. 2004. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. *Exp Dermatol* 13:380.
126. Bukowski, R. M., P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, A. Novick, T. A. Hamilton, and J. Finke. 1999. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. *Clin Cancer Res* 5:2780.
127. Colombo, M. P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, and A. Stoppacciaro. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. *Cancer Res* 56:2531.
128. Cebon, J., E. Jager, M. J. Shackleton, P. Gibbs, I. D. Davis, W. Hopkins, S. Gibbs, Q. Chen, J. Karbach, H. Jackson, D. P. MacGregor, S. Sturrock, H. Vaughan, E. Maraskovsky, A. Neumann, E. Hoffman, M. L. Sherman, and A. Knuth. 2003. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. *Cancer Immun* 3:7.
129. Wadler, S., D. Levy, H. L. Frederickson, C. I. Falkson, Y. Wang, E. Weller, R. Burk, G. Ho, and A. S. Kadish. 2004. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. *Gynecol Oncol* 92:957.
130. Egilmez, N. K., Y. S. Jong, M. S. Sabel, J. S. Jacob, E. Mathiowitz, and R. B. Bankert. 2000. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. *Cancer Res* 60:3832.
131. Gollob, J. A., K. G. Veenstra, J. W. Mier, and M. B. Atkins. 2001. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. *J Immunother* 24:91.
132. Sangro, B., G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, C. Olague, J. Sola, B. Sadaba, C. Lacasa, I. Melero, C. Qian, and J. Prieto. 2004. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. *J Clin Oncol* 22:1389.
133. Ren, H., T. Boulikas, K. Lundstrom, A. Soling, P. C. Warnke, and N. G. Rainov. 2003. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. *J Neurooncol* 64:147.

134. Quezada, A., M. J. Horner, D. Loera, M. French, F. Pericle, R. Johnson, J. Perrard, M. Jenkins, and M. Coleman. 2002. Safety toxicity study of plasmid-based IL-12 therapy in Cynomolgus monkeys. *J Pharm Pharmacol* 54:241.
135. Rook, A. H., T. M. Kuzel, and E. A. Olsen. 2003. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. *Hematol Oncol Clin North Am* 17:1435.